Abstract
2600 Background: The implementation of the 2005 ICH E14 has included clinical evaluation of QTc prolongation for Therapeutic Biotechnology Products (TBPs). The ability of monoclonal antibodies (mAb...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have